420
Views
11
CrossRef citations to date
0
Altmetric
Review

Bloodstream infections in intensive care unit patients: distribution and antibiotic resistance of bacteria

, , , , , & show all
Pages 287-296 | Published online: 10 Aug 2015

Abstract

Bloodstream infections (BSIs) are among the leading infections in critically ill patients. The case-fatality rate associated with BSIs in patients admitted to intensive care units (ICUs) reaches 35%–50%. The emergence and diffusion of bacteria with resistance to antibiotics is a global health problem. Multidrug-resistant bacteria were detected in 50.7% of patients with BSIs in a recently published international observational study, with methicillin resistance detected in 48% of Staphylococcus aureus strains, carbapenem resistance detected in 69% of Acinetobacter spp., in 38% of Klebsiella pneumoniae, and in 37% of Pseudomonas spp. Prior hospitalization and antibiotic exposure have been identified as risk factors for infections caused by resistant bacteria in different studies. Patients with BSIs caused by resistant strains showed an increased risk of mortality, which may be explained by a higher incidence of inappropriate empirical therapy in different studies. The molecular genetic characterization of resistant bacteria allows the understanding of the most common mechanisms underlying their resistance and the adoption of surveillance measures. Knowledge of epidemiology, risk factors, mechanisms of resistance, and outcomes of BSIs caused by resistant bacteria may have a major influence on global management of ICU patients. The aim of this review is to provide the clinician an update on BSIs caused by resistant bacteria in ICU patients.

Introduction

Bloodstream infections (BSIs) are among the leading acquired infections in intensive care unit (ICU) patients.Citation1 BSIs may be the consequence of the bloodstream diffusion of bacteria from a localized infection (secondary BSI) or may be the only identifiable infectious process (primary BSI). Antimicrobial therapy is the mainstay of treatment of BSIs, along with management of severe sepsis and septic shock that may eventually develop.Citation2 During these last few years, clinicians have witnessed a growing incidence of BSIs by bacteria with resistance against commonly used antimicrobials.Citation3 A multidrug-resistant (MDR) microorganism has been defined as an isolate with nonsusceptibility to at least one agent in three or more antimicrobial categories. Extensive drug-resistant (DR) microorganisms exhibit susceptibility to only one or two antimicrobial categories, whereas pan-DR isolates are those microorganisms resistant to all agents from all antimicrobial categories.Citation4 Emergence of resistance among bacteria is considered a public health problem worldwide.Citation5 BSIs caused by MDR microorganisms are associated with excess mortality, which may be attributed, at least in part, to the delay in appropriate therapy institution.Citation6Citation8 Emergence of resistant bacteria in the ICU implies an even higher challenge for the clinician, dealing with seriously ill patients, who need prompt institution of effective antimicrobial therapy in a setting of higher prevalence of resistant isolates, broad-spectrum antibiotic, use and ease of cross-transmission of resistant microorganisms.Citation2,Citation9,Citation10 The clinician should be aware of the main risk factors for BSIs sustained by resistant bacteria in the ICU, the most commonly met resistant species according to different geographic areas, and their mechanisms of resistance. The aim of this review is to provide the clinician an update on BSI caused by resistant bacteria in ICU patients.

Epidemiology of BSIs caused by resistant bacteria

BSIs are among the leading infections in ICUs. In an international study of the prevalence and outcomes of infections in ICUs, BSIs were observed in 15% of infected patients and represented the third-most commonly met infection.Citation1 The traditional classification of BSIs between community-acquired and hospital-acquired is being reconsidered in light of the evolving health care-system organization. A growing proportion of patients, with older age and several comorbidities, are treated as outpatients, with a shift of health care services from hospitals to the community with different out-of-hospital facilities.Citation11,Citation12 In this sense, health care-associated BSIs have been defined as those occurring in patients living in a nursing home or long-term care facilities, receiving health care at home, under hemodialysis, intravenous chemotherapy, wound care, or enteral nutrition, or who recently accessed an acute care hospital.Citation11 Approximately one in five BSIs diagnosed at ICU admission may be classified as health care-associated BSIs.Citation13 Pathogens responsible for health care-associated BSIs are similar to those isolated from hospital-acquired BSIs, with a higher risk of resistant isolates compared to community-acquired BSIs. A higher incidence of inappropriate empirical therapy and a trend of increased mortality has also been detected in different studies.Citation13,Citation14 A recently published international observational study provided information about hospital-acquired BSIs from 1,156 ICU patients worldwide.Citation10 Among total microorganisms causing BSI, 57.6% were Gram-negative and 33.4% were Gram-positive. MDR bacteria caused BSIs in 50.7% of patients, and extensive DR bacteria were detected in 22% of patients. Among Gram-negative bacteria, carbapenem resistance was detected in 69% of Acinetobacter spp, 38% of Klebsiella pneumoniae, and 37% of Pseudomonas spp. Among Gram-positive bacteria, 48% of Staphylococcus aureus isolates were methicillin-resistant Staphylococcus aureus (MRSA), and 23% of Enterococcus faecium isolates were vancomycin-resistant enterococci (VRE). With regard to the source of BSIs, in 21.1% they was attributed to the respiratory tract, and in 21.4% BSIs were catheter-related. In 23.7% of total patients, no clear source of infection was identified. These data are similar to those of the recently published French national network REA RAISIN of ICU-acquired bacteremia (29.2% catheter-related, 18% lower respiratory tract infections).Citation10,Citation15 According to a large observational study investigating the trend of BSIs caused by resistant bacteria over a period of 10 years, resistant isolates represented an additional burden of disease rather than substituting susceptible bacteria as the cause of BSIs.Citation3 In the modern globalized world, antibiotic-resistant bacteria can be easily distributed across countries by human travelers, animal and insect vectors, agricultural products, and water.Citation16 Analysis of genetic material encoding antibiotic resistance has been used for tracing the diffusion of resistant strains both at a local and international level.Citation17 An example is the worldwide distribution of MDR staphylococci from very few resistant clones.Citation18 Rapid detection of resistant bacteria and their genetic characterization through molecular techniques is therefore a pivotal component of surveillance and control of diffusion of resistant bacteria from a single institution to a global level.Citation19,Citation20

Risk factors for BSI caused by resistant bacteria

Patients in ICUs have different risk factors for BSI development, including greater severity of illness, disruption of anatomical barriers (ie, use of invasive devices, surgery), and impaired immunological response.Citation2 Patients with a central vein catheter (CVC) have additional risk factors for catheter-related BSIs (inadequate adoption of a sterile technique, inexperience of the operator, site of insertion, colonization of the insertion site, contamination of the catheter hub, and duration of catheter placement).Citation21Citation23 Different observational studies have described risk factors for BSIs caused by resistant bacteria.Citation10Citation12,Citation24 In general, prior antibiotic exposure and hospitalization, residency in nursing home and in long-term care facilities, and other described risk factors for health care-related BSIs are associated with an increased risk of developing a BSI caused by resistant microorganisms.Citation13,Citation25Citation27 In a retrospective study of patients with severe sepsis and septic shock attributed to bacteremia caused by Gram-negative microorganisms, prior antibiotic exposure was associated with a reduced susceptibility to cefepime, piperacillin/tazobactam, carbapenems, ciprofloxacin, and gentamicin. Moreover, patients with recent antibiotic exposure more frequently received inappropriate empirical antimicrobial therapy and had higher hospital mortality.Citation26 Patients with BSIs caused by carbapenem-resistant K. pneumoniae more frequently had a CVC or urinary catheter compared to patients with BSIs caused by susceptible microorganisms, received renal replacement therapy or prior antibiotic treatment, and were more likely hospitalized in a ward with other resistant isolates during the 30 days preceding the BSI diagnosis.Citation25 Colonization was identified as a significant risk factor for subsequent development of bacteremia by Acinetobacter baumannii in different studies.Citation9,Citation28,Citation29 Patients were frequently colonized by MDR A. baumannii after approximately 7 days from ICU admission, with respiratory and urinary tracts the most commonly detected colonized sites.Citation9 Reported risk factors for subsequent development of bacteremia by MDR A. baumannii in previously colonized patients were respiratory failure at ICU admission treated with invasive mechanical ventilation, recent CVC insertion, prior antibiotic therapy, and development of bacteremia caused by other microorganisms after MDR A. baumannii colonization.Citation29 Knowledge of risk factors for BSIs caused by resistant bacteria may have a major influence on global management in ICUs, from source-control and surveillance measures to appropriate antibiotic treatment.Citation19

Mechanisms of antibacterial drug resistance

Antibiotic resistance is a complex phenomenon that encompasses recognized in vitro mechanisms and their phenotypic expression, but also – at the clinical level – infection site, pharmacodynamic/pharmacokinetic properties of the specific antibiotic, modification of these pharmacological profiles in the critically ill patient, and immune status.Citation30,Citation31 Resistance patterns of bacteria at a cellular level may be generally classified as follows: altered target site, namely modification of the molecule that is the target of the antimicrobial action; decreased antimicrobial uptake through decreased permeability to the antimicrobial or its elimination by efflux pumps; bypass pathways, which overcome the inhibition caused by the antibiotic molecule; and inactivation of the antimicrobial molecule through the production of enzymes that inactivate the drug.Citation31 Antibiotic resistance may represent an intrinsic property of different bacteria (eg, low permeability to some molecules), or rather may be acquired as a consequence of antibiotic pressure or mobile genetic element transmission.Citation32,Citation33

summarizes the most commonly described resistance mechanisms of bacteria against frequently used antibacterial agents in ICU, with the corresponding genes identified to date.

Table 1 Mechanisms of resistance against most commonly used antimicrobial agents and corresponding genes expressed by bacteria

Enterococcus spp

Enterococci are Gram-positive, facultatively anaerobic, opportunistic bacteria. E. faecalis and E. faecium are the leading species responsible of human disease. VRE, which emerged during the late 1980s,Citation34 are among the major health care-associated MDR organisms.Citation10 Enterococci are normal components of the human intestinal flora, but may become responsible for serious infections, such as BSIs and intra-abdominal and surgical site infections, especially among immunocompromised patients.Citation35 These microorganisms represent the third-most prevalent nosocomial pathogens worldwide, and acquired resistance to penicillin/ampicillin, aminoglycosides, and glycopeptides are reported in an increasing number of isolates, causing a serious problem in choosing an appropriate therapy.Citation36 All Enterococcus spp., including E. faecalis and E. faecium, are naturally resistant to several antibiotics, such as cephalosporins, clindamycin, co-trimoxazole, and aminoglycosides.Citation37 Mechanisms of glycopeptide resistance in enterococci have been well investigated, and to date we know of nine mobile gene clusters that mediate the resistance: VanA, VanB, VanC, VanD, VanE, VanG, VanL, VanM, and VanN. VanA resistance is the most prevalent, and confers high-level resistance to all glycopeptides by altering the terminal sequence of cell-wall precursors, thus lowering their binding affinity, while the VanB phenotype is only resistant to vancomycin.Citation37 VRE isolates exhibit a genetic “pathogenicity island”, coding for a putative enterococcal surface protein.Citation38 This protein produces thicker and DR biofilms, and its expression in E. faecium is regulated by temperature, promoting initial colonization and aiding in biofilm formation. Thanks to the ability to colonize gut, skin, and inanimate surfaces, this trait is likely to promote the infection of indwelling medical devices, of which enterococci are frequently associated.Citation39 Of note, vancomycin-resistance genes can be transferred from enterococci to other organisms, causing the emergence of vancomycin-resistant S. aureus (VRSA).Citation40

S. aureus

S. aureus is a Gram-positive, facultative anaerobic pathogen, with both hospital- and community-acquired strains. It is part of the microbiota of the skin, and it is most commonly isolated from moist areas, such as the anterior nares and axillae.Citation41 Traditionally opportunistic, many S. aureus strains are now aggressively pathogenic, causing a wide range of diseases, from skin and wound infections to severe illnesses, such as BSIs and soft-tissue and bone infections.Citation41,Citation42 As enterococci, S. aureus also frequently causes chronic infections by forming biofilms, and this is the leading cause of chronic infections associated with indwelling medical devices.Citation43 MRSA is a major pathogen in both health care and community settings, and its resistance is conferred by the acquisition of one of several staphylococcal cassette chromosome mec elements that carry a gene (mecA) that encodes a penicillin-binding protein (PBP2a) with low affinity for β-lactam antibiotics.Citation44,Citation45 One of the most challenging issues in the evolution of MRSA epidemiology is the emergence and spread of community-acquired MRSA. These strains are generally susceptible to a wider spectrum of non-β-lactam antibiotics compared to hospital-acquired MRSA, but they often carry the genes for Panton–Valentine leukocidin.Citation46,Citation47 First-line treatment for MRSA infections is glycopeptide antibiotics (ie, vancomycin or teicoplanin). However, the intensive selective pressure caused the emergence of vancomycin-intermediate S. aureus and VRSA.Citation42 Vancomycin-intermediate S. aureus strains have evolved as a result of fundamental changes in cell-wall thickness and composition, trapping vancomycin and reducing its permeation to the site of action. VRSA is far less common, and is characterized by an acquired resistance from the VRE vanA gene, which alters the terminal sequence of cell-wall precursors, making them poor substrates for vancomycin and teicoplanin. MDR VRSA isolates exhibit both mecA and vanA resistance genes, with resistance being conferred through the same mechanisms as MRSA and VRE, respectively.Citation48

Enterobacteriaceae

The emergence of resistance in Enterobacteriaceae is considered an alarming health threat.Citation49 During these last few years, a growing number of K. pneumoniae, E. coli, and Enterobacter spp. have developed resistance against third-generation cephalosporin, due to extended-spectrum β-lactamases (ESBLs). ESBLs evolved from BLs, which are frequently expressed in Gram-negative bacteria (TEM-1, TEM-2, SHV-1) and are responsible for resistance against ampicillin, amoxicillin, and early generations of cephalosporins.Citation49,Citation50 Mutations in genes encoding these BLs led to the evolution of new enzymes, able to also hydrolyze third-generation cephalosporins and aztreonam. More than 700 ESBLs variants have been identified to date, some of which have spread rapidly worldwide.Citation50,Citation51 Different classifications of BLs have been proposed, though Bush functional classificationCitation52 and Ampler molecular classification are the most commonly used.Citation53 The diffusion of coding genes for ESBLs through mobile genetic elements is responsible for their ease of diffusion, their transmission in bacteria different from Enterobacteriaceae (ie, nonfermenting, Gram-negative rods, such as Pseudomonas aeruginosa), and cotransmission of genes responsible of resistance against other classes of molecules (eg, aminoglycosides).Citation50 Carbapenems are the first line treatment of ESBLs producing bacteria, and the emergence of carbapenem-resistant isolates leaves limited therapeutic options.Citation54,Citation55 Metallo-BLs (MBLs), extended-spectrum oxacillinases, and clavulanic acid-inhibited BLs have all been isolated in Enterobacteriaceae.Citation50 MBLs belonging to class B of the Ambler classification (Verona imipenemase [VIM], imipenemase [IMP]) have been detected in different countries.Citation55 Class D OXA-48 β-lactamases have been detected in K. pneumoniae isolates from Turkey, Lebanon, and Belgium.Citation55Citation57 Among class A β-lactamases, the most commonly identified enzyme is KPC.Citation55 The first KPC-producing K. pneumoniae isolate was detected in North Carolina, USA, in 1996.Citation58 This first discovery was followed by several other variants (KPC-2 to KPC-7).Citation55 Of note, several KPC-producing K. pneumoniae with susceptibility to carbapenems have been reported, underlying the need of an additional mechanism (eg, poor drug penetration) for full expression of drug resistance.Citation59 Apart from enzymatic inactivation of drug molecules, different mechanisms of virulence and additional antibiotic-resistance mechanisms have been described in Enterobacteriaceae.Citation49 K. pneumoniae is intrinsically virulent and capable of invasive infections, due to fimbrial adhesins and a thick capsule, which acts as a putative antiphagocytic factor.Citation60 Pan-DR strains of KPC-producing K. pneumoniae have been reported in the literature, and isolates were resistant to all antibiotic agents tested, including carbapenems, polymyxin B, and tigecycline.Citation55 Polymyxins are considered the last resort for treatment of infections with carbapenem-resistant Gram-negative bacteria.Citation61 However, resistance to these compounds has begun to emerge, though infrequently. Selective pressure, by the increased use of colistin, and clonal expansion through horizontal transmission, have generated clusters of cases infected with multiresistant K. pneumoniae strains that have been generally attributed to the international epidemic clone ST258. Mono- or multiclonal outbreaks of colistin-resistant, KPC-producing K. pneumoniae have been described in hospitals in many countries, for example Greece, South Korea, the USA, and Italy.Citation62,Citation63 Altered outer-membrane composition with the phosphate groups of lipid A containing five times more l-Ara4N than susceptible strains is known to lower the negative charge of the outer membrane of K. pneumoniae, leading to the reduced interaction of this membrane with polymyxins.Citation64 A molecular characterization of the structural alterations of lipopolysaccharide (LPS) in K. pneumoniae with regard to polymyxin resistance has shown the involvement of the phoP/phoQ and pmrA/pmrB genes.Citation65 One important molecular mechanism that leads to the emergence of colistin resistance in K. pneumoniae that has recently been discovered is the mutation/inactivation of the mgrB gene.Citation66 Disruption of the mgrB gene in K. pneumoniae has been identified to play an important role in polymyxin resistance in this bacterium.Citation67 Polymyxins remain most often active against MDR bacteria, and the emergence of colistin resistance in relation to increased usage is worrisome, since polymyxins are the last remaining therapeutic option in many cases.Citation68

E. coli are Gram-negative, facultative anaerobes, most commonly commensal, but can also become pathogenic, producing potentially deadly toxins, including enterohemorrhagic verotoxins, such as E. coli O157:H7, which causes hemolytic uremic syndrome and renal failure.Citation69 E. coli has been one of the most widely antibiotic-susceptible microorganisms of the Enterobacteriaceae family, but recently horizontal gene transfer has allowed for the rise of highly resistant strains.Citation70 This spread of resistance has major relevance, because these strains are among the most common Gram-negative bacteria causing infections in humans. Strains carrying ESBLs and with high coresistance to fluoroquinolones and gentamicin have been rising in Europe.Citation71 Even if still uncommonly, in multiple continents E. coli have also acquired the NDM-1 enzyme from K. pneumoniae, which confers a broad resistance to all BLs, including carbapenems, with the exception of the monobactam aztreonam.Citation72 In polymyxin-resistant E. coli, lipid A is typically modified with 2-aminoethanol and also with l-Ara4N.Citation73

Enterobacter is a genus of Gram-negative, facultative anaerobic, opportunistic pathogens, possessing endotoxins and antibiotic resistance through expression of an extensive variety of ESBLs and carbapenemases, including KPC, OXA, and MBLs.Citation74 Of note, Enterobacter spp. are intrinsically resistant to aminopenicillins, cefazolin, and cefoxitin, due to the production of constitutive chromosomal AmpC BLs.Citation75

Nonfermenting Gram-negative bacteria

A. baumannii

The most common resistant Acinetobacter species is A. baumannii, a Gram-negative, facultative anaerobic, opportunistic pathogen. It has a thick cell wall that enables it to resist dry conditions, high temperature, and pH and nutrient changes, surviving for up to 5 months on inanimate objects.Citation76 A. baumannii is naturally resistant to many antibiotics, due to both poor membrane penetration and active efflux pumps. Overexpression of the AdeABC and AbeM efflux pumps causes broad resistance to cephalosporins, fluoroquinolones, aminoglycoside, and tigecycline, and also provides resistance to ammonia-based disinfectants.Citation77 Furthermore, A. baumannii isolates produce an exopolysaccharide, leading to biofilm formation, and express a powerful, epithelial cell-targeting cytotoxin that facilitates colonization.Citation78 MDR A. baumannii expresses a variety of BLs, including ESBLs and carbapenemases, such as imipenem MBLs and oxacillinases.Citation79 Among naturally occurring BLs, an AmpC-type cephalosporinase and OXA-51/69 variants have been identified. These enzymes, once overexpressed, may be involved in reduced susceptibility to carbapenems. Most acquired BLs belong to class B or class D of the Ambler classification. OXA-23-like enzymes are the most widespread in A. baumannii worldwide, and these bacteria are the most common sources of nosocomial outbreaks with carbapenem-resistant A. baumannii.Citation80 A. baumannii worldwide shows high-level resistance to all aminoglycosides by decreased outer-membrane permeability, active efflux pumps, and amino acid substitutions in ribosomal proteins.Citation31 In P. aeruginosa and A. baumannii, a single mutation in the gyrA gene encoding DNA gyrase is sufficient to confer clinically high-level resistance to fluoroquinolones. Of note, decreased susceptibility to this class of molecules is also due to low permeability and efflux-pump activity.Citation81 Resistance to tigecycline has been noted on several occasions, and might be due to upregulation of the AdeABC and AdeIJK multi-drug efflux-pump systems.Citation82 Tigecycline-resistance levels in A. baumannii isolates may increase during therapy in cases of brief exposure to the drug, compromising its efficacy.Citation82,Citation83 Two mechanisms of resistance to colistin have been described in A. baumannii. The first consists of alterations of the lipid A component of LPS resulting from mutations in the PmrAB two-component system.Citation32,Citation84 The second resistance mechanism is the complete loss of LPS production resulting from mutations in the lpxA, lpxC, and lpxD genes, encoding the enzymes that catalyze the first steps in LPS biosynthesis.Citation85

P. aeruginosa

P. aeruginosa is a Gram-negative, rod-shaped bacterium, a facultative anaerobic, opportunistic pathogen surviving in microaerobic conditions, such as the thick mucus of lungs of cystic fibrosis patients. The ubiquity and survival capacity in extreme environments, like antimicrobial solutions of acetate-buffered benzalkonium chloride, are major determinants of outbreaks of nosocomial infections. It has a high propensity to form biofilms. Its outer-membrane porins make it impermeable and resistant to many antibiotics.Citation86,Citation87 P. aeruginosa is notoriously resistant to fluoroquinolones as a result of target mutations on DNA gyrase and/or topoisomerase IV.Citation33 Many BLs, encoded by plasmids or chromosomally integrated transposons, have been reported (eg, IMP, VIM, KPC, and SPM metallocarbapenemases).Citation88 An acquired ceftazidimase ESBL called PER-1 is widespread in P. aeruginosa isolated in Turkey.Citation89 IMP and VIM enzymes are integron-associated and can be plasmid-mediated and transferable, although chromosomal gene integration is common.Citation88 IMP-1 was first reported in Enterobacteriaceae and P. aeruginosa in Japan and is now globally distributed, suggesting horizontal transfer of blaIMP-1 between unrelated Gram-negative species.Citation79 VIM-1 was the first MBL identified in P. aeruginosa and has been reported in several European countries. However, VIM-2 is now the most widespread MBL as a source of multiple outbreaks.Citation90 The BL SPM is quite different from VIM and IMP, and represents a new subfamily of MBLs, highly resistant to all anti-Gram-negative antibiotics except colistin.Citation91 Intrinsic to P. aeruginosa is a chromosomal gene encoding an AmpC-type cephalosporinase, associated with a LysR-type regulatory gene with which some BL molecules may interact, leading to overexpression of the AmpC gene. Selection of mutants overproducing the AmpC gene is frequently observed in P. aeruginosa, leading to acquired resistance to ticarcillin, piperacillin, and broad-spectrum cephalosporins (ceftazidime).Citation83,Citation92 P. aeruginosa produces a naturally occurring class D BL, OXA-50, that does not contribute to the overall BL-resistance pattern of P. aeruginosa, except for latamoxef.Citation93 Most of the class D BLs able to hydrolyze expanded-spectrum cephalosporins have been identified, and there are two main types of expanded-spectrum class D BLs (ES-OXAs).Citation94 OXA-18, which is inhibited by clavulanic acid, was the first identified ES-OXA in a P. aeruginosa isolate in Paris, from a patient previously hospitalized in Sicily.Citation95 Only two acquired class D BLs, compromising the efficacy of carbapenems, have been reported from P. aeruginosa: OXA-40 and OXA-198.Citation96,Citation97 Resistance to tigecycline has been noted on several occasions, and might be due to upregulation of the AdeABC and AdeIJK multidrug efflux pumps acting synergistically.Citation98 Acquisition of polymyxin resistance is mostly related to modifications of the biosynthesis of the lipid A component of LPS. This resistance is mediated by a complicated regulatory genetic network, such as PmrAB, PhoPQ, ParRS, CprRS, and ColRS, which is currently under investigation worldwide.Citation61

Outcomes

The overall case-fatality rate associated with BSIs is 15%–20%, but reaches 35%–50% when patients with ICU admission are considered.Citation2 In most observational studies investigating the epidemiology and outcomes of BSIs due to resistant bacteria, inappropriate antimicrobial therapy is independently associated with an increased mortality after correction for severity of illness and other potential confounders.Citation8,Citation10,Citation25,Citation99 The risk of inappropriate empirical therapy increases with the prevalence of resistant microorganisms.Citation25 It is generally accepted that the increased risk of mortality attributable to BSIs due to resistant isolates is related to inappropriate therapeutic choices, rather than intrinsic enhanced virulence of resistant microorganisms.Citation25 The overall mortality of patients with BSIs due to carbapenem-resistant K. pneumoniae was 23% at 7 days and 60% at the end of hospitalization in a retrospective observational study. Lack of microbiologic eradication at 7 days was associated with an increased 30-day mortality.Citation100 A higher infection-related mortality was detected in patients with BSIs caused by carbapenem-resistant K. pneumoniae compared to those with ESBL K. pneumoniae or susceptible strains. This increased mortality may be explained by the higher proportion of patients with ineffective antimicrobial therapy in the carbapenem-resistant group.Citation25 Apart from previously reported risk factors (recent history of hospitalization, critical illness at presentation, inappropriate empirical therapy), postantibiogram antimicrobial regimens had an influence on 30-day mortality from carbapenem-resistant K. pneumoniae BSIs, with a higher risk of mortality observed in monotherapy-treated patients compared to patients treated with combination therapy, especially when the combination regimen included a carbapenem.Citation54 The unexpected observation of improved outcomes when carbapenemase-producing isolates of K. pneumoniae are treated with carbapenems confirmed previously reported data from case reports and retrospective studies.Citation101,Citation102

Conclusion

BSIs are among the leading causes of infections in ICU patients. An increasing number of BSIs are caused by resistant bacteria in the ICU setting. The clinician should be aware of the risk factors for BSIs caused by resistant bacteria, common resistance mechanisms, and their diffusion for the global management of critically ill patients, from surveillance measures to source control and appropriate antibiotic treatment.

Disclosure

The authors report no conflicts of interest in this work.

References

  • VincentJLRelloJMarshallJInternational study of the prevalence and outcomes of infection in intensive care unitsJAMA2009302212323232919952319
  • TimsitJFLauplandKBUpdate on bloodstream infections in ICUsCurr Opin Crit Care201218547948622820156
  • AmmerlaanHHarbarthSBuitingASecular trends in nosocomial bloodstream infections: antibiotic-resistant bacteria increase the total burden of infectionClinical Infect Dis201356679880523223600
  • MagiorakosAPSrinivasanACareyRMultidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistanceClin Microbiol Infect201218326828121793988
  • CarletJCollignonPGoldmannDSociety’s failure to protect a precious resource: antibioticsLancet2011378978836937121477855
  • RetamarPPortilloMMLópez-PrietoMDImpact of inadequate empirical therapy on the mortality of patients with bloodstream infections: a propensity score-based analysisAntimicrob Agents Chemother201256147247822005999
  • ZarkotouOPournarasSTseliotiPPredictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatmentClin Microbiol Infect201117121798180321595793
  • KangCIKimSHParkWBBloodstream infections caused by antibiotic-resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcomeAntimicrob Agents Chemother200549276076615673761
  • JungJYParkMSKimSERisk factors for multi-drug resistant Acinetobacter baumannii bacteremia in patients with colonization in the intensive care unitBMC Infect Dis20101022820670453
  • TabahAKoulentiDLauplandKCharacteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort StudyIntensive Care Med201238121930194523011531
  • Rodríguez-BañoJLópez-PrietoMDPortilloMMEpidemiology and clinical features of community-acquired, healthcare-associated and nosocomial bloodstream infections in tertiary-care and community hospitalsClin Microbiol Infect20101691408141319845694
  • KollefMHZilberbergMDShorrAFEpidemiology, microbiology and outcomes of healthcare-associated and community-acquired bacteremia: a multicenter cohort studyJ Infect201162213013521195110
  • VallésJAlvarez-LermaFPalomarMHealth-care-associated bloodstream infections at admission to the ICUChest2011139481081521106655
  • McDonaldJRFriedmanNDStoutJESextonDJKayeKSRisk factors for ineffective therapy in patients with bloodstream infectionArch Intern Med2005165330831315710794
  • TimsitJFSoubirouJFVoiriotGTreatment of bloodstream infections in ICUsBMC Infect Dis20141448925431091
  • OkekeINEdelmanRDissemination of antibiotic-resistant bacteria across geographic bordersClin Infect Dis200133336436911438903
  • Al NaiemiNDuimBSavelkoulPHWidespread transfer of resistance genes between bacterial species in an intensive care unit: implications for hospital epidemiologyJ Clin Microbiol20054394862486416145160
  • AyliffeGThe progressive intercontinental spread of methicillin-resistant Staphylococcus aureusClin Infect Dis199724Suppl 1S74S798994782
  • MonteroJGLermaFÁGalleymorePRCombatting resistance in intensive care: the multimodal approach of the Spanish ICU “Zero Resistance” programCrit Care20151911425880421
  • CortegianiARussottoVCapuanoPUse of Cepheid Xpert Carba-R® for rapid detection of carbapenemase-producing bacteria in critically ill, abdominal surgical patients: first report of an observational studyCrit Care201519Suppl 110825881121
  • PronovostPNeedhamDBerenholtzSAn intervention to decrease catheter-related bloodstream infections in the ICUN Engl J Med2006355262725273217192537
  • BerenholtzSMPronovostPJLipsettPAEliminating catheter-related bloodstream infections in the intensive care unitCrit Care Med200432102014202015483409
  • FridkinSKPearSMWilliamsonTHGalgianiJNJarvisWRThe role of understaffing in central venous catheter-associated bloodstream infectionInfect Control Hosp Epidemiol19961731501588708352
  • ElemamARahimianJMandellWInfection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literatureClin Infect Dis200949227127419527172
  • Ben-DavidDKordevaniRKellerNOutcome of carbapenem resistant Klebsiella pneumoniae bloodstream infectionsClin Microbiol Infect2012181546021722257
  • JohnsonMTReichleyRHoppe-BauerJDunneWMMicekSKollefMImpact of previous antibiotic therapy on outcome of Gram-negative severe sepsisCrit Care Med20113981859186521499086
  • MarschallJFraserVJDohertyJWarrenDKBetween community and hospital: healthcare-associated Gram-negative bacteremia among hospitalized patientsInfect Control Hosp Epidemiol200930111050105619803723
  • ShihMJLeeNYLeeHCRisk factors of multidrug resistance in nosocomial bacteremia due to Acinetobacter baumannii: a case-control studyJ Microbiol Immunol Infect200841211812318473098
  • JangTNLeeSHHuangCHLeeCLChenWYRisk factors and impact of nosocomial Acinetobacter baumannii bloodstream infections in the adult intensive care unit: a case-control studyJ Hosp Infect200973214315019716203
  • ThomasJKForrestABhavnaniSMPharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapyAntimicrob Agents Chemother19984235215279517926
  • HatcherJDhillonRAzadianBSAntibiotic resistance mechanisms in the intensive care unitJ Intensive Care Soc2012134297303
  • OlaitanAOMorandSRolainJMMechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteriaFront Microbiol2014564325505462
  • LivermoreDMMultiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?Clin Infect Dis200234563464011823954
  • UttleyACCollinsCNaidooJGeorgeRVancomycin-resistant enterococciLancet1988331857557582891921
  • ElsnerHASobottkaIMackDLaufsRClaussenMWirthRVirulence factors of Enterococcus faecalis and Enterococcus faecium blood culture isolatesEur J Clin Microbiol Infect Dis2000191394210706178
  • AriasCMurrayBEmergence and management of drug-resistant enterococcal infectionsExpert Rev Anti Infect Ther20086563765518847403
  • HollenbeckBLRiceLBIntrinsic and acquired resistance mechanisms in enterococcusVirulence20123542143323076243
  • ShankarNBaghdayanASGilmoreMSModulation of virulence within a pathogenicity island in vancomycin-resistant Enterococcus faecalisNature2002417689074675012066186
  • Van WamelWJHendrickxAPBontenMJTopJPosthumaGWillemsRJGrowth condition-dependent Esp expression by Enterococcus faecium affects initial adherence and biofilm formationInfect Immun200775292493117118984
  • LeclercqREpidemiological and resistance issues in multidrug-resistant staphylococci and enterococciClin Microbiol Infect2009153224223119335370
  • LowyFStaphylococcus aureus infectionsN Engl J Med199833985205329709046
  • ChambersHFDeLeoFRWaves of resistance: Staphylococcus aureus in the antibiotic eraNat Re Microbiol200979629641
  • CostertonJStewartPSGreenbergEBacterial biofilms: a common cause of persistent infectionsScience199928454181318132210334980
  • KatayamaYItoTHiramatsuKA new class of genetic element, Staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureusAntimicrob Agents Chemother20004461549155510817707
  • UtsuiYYokotaTRole of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureusAntimicrob Agents Chemother19852833974033878127
  • GeraciDBonuraCGiuffrèMtst1-Positive ST22-MRSA-IVa in healthy Italian preschool childrenInfection201442353553824448875
  • Lamaro-CardosoJde LencastreHKipnisAMolecular epidemiology and risk factors for nasal carriage of Staphylococcus aureus and methicillin-resistant S. aureus in infants attending day care centers in BrazilJ Clin Microbiol200947123991399719828745
  • AppelbaumPCReduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA)Int J Antimicrob Agents200730539840817888634
  • PatersonDLResistance in gram-negative bacteria: EnterobacteriaceaeAm J Med20061196 Suppl 1S20S2816735147
  • PitoutJDLauplandKBExtended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concernLancet Infect Dis20088315916618291338
  • HawserSPBouchillonSKHobanDJBadalREHsuehPRPatersonDLEmergence of high levels of extended-spectrum-β-lactamase-producing Gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007Antimicrob Agents Chemother20095383280328419506060
  • BushKJacobyGAMedeirosAAA functional classification scheme for beta-lactamases and its correlation with molecular structureAntimicrob Agents Chemother1995396121112337574506
  • HallBGBarlowMRevised Ambler classification of β-lactamasesJ Antimicrob Chemother20055561050105115872044
  • TumbarelloMVialePViscoliCPredictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapyClin Infect Dis201255794395022752516
  • NordmannPCuzonGNaasTThe real threat of Klebsiella pneumoniae carbapenemase-producing bacteriaLancet Infect Dis20099422823619324295
  • MatarGCuzonGArajGOxacillinase-mediated resistance to carbapenems in Klebsiella pneumoniae from LebanonClin Microbiol Infect200814988788818844693
  • CuzonGNaasTBogaertsPGlupczynskiYHuangTDNordmannPPlasmid-encoded carbapenem-hydrolyzing β-lactamase OXA-48 in an imipenem-susceptible Klebsiella pneumoniae strain from BelgiumAntimicrob Agents Chemother20085293463346418644970
  • YigitHQueenanAMAndersonGJNovel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniaeAntimicrob Agents Chemother20014541151116111257029
  • ZhangRYangLCaiJCZhouHWChenGXHigh-level carbapenem resistance in a Citrobacter freundii clinical isolate is due to a combination of KPC-2 production and decreased porin expressionJ Med Microbiol200857333233718287296
  • PodschunRUllmannUKlebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factorsClin Microbiol Rev19981145896039767057
  • GutuADSgambatiNStrasbourgerPPolymyxin resistance of Pseudomonas aeruginosa phoQ mutants is dependent on additional two-component regulatory systemsAntimicrob Agents Chemother20135752204221523459479
  • MezzatestaMGonaFCaioCOutbreak of KPC-3-producing, and colistin-resistant, Klebsiella pneumoniae infections in two Sicilian hospitalsClin Microbiol Infect20111791444144721668577
  • MamminaCBonuraCDi BernardoFOngoing spread of colistin-resistant Klebsiella pneumoniae in different wards of an acute general hospital, Italy, June to December 2011Euro Surveill2012173314
  • VelkovTDerisZZHuangJXSurface changes and polymyxin interactions with a resistant strain of Klebsiella pneumoniaeInnate Immun201420435036323887184
  • ChengHYChenYFPengHLMolecular characterization of the PhoPQ-PmrD-PmrAB mediated pathway regulating polymyxin B resistance in Klebsiella pneumoniae CG43J Biomed Sci2010176020653976
  • CannatelliAD’AndreaMMGianiTIn vivo emergence of colistin resistance in Klebsiella pneumoniae producing KPC-type carbapenemases mediated by insertional inactivation of the PhoQ/PhoP mgrB regulatorAntimicrob Agents Chemother201357115521552623979739
  • OlaitanAODieneSMKempfMWorldwide emergence of colistin resistance in Klebsiella pneumoniae from healthy humans and patients in Lao PDR, Thailand, Israel, Nigeria and France owing to inactivation of the PhoP/PhoQ regulator mgrB: an epidemiological and molecular studyInt J Antimicrob Agents201444650050725264127
  • CarletJMainardiJLAntibacterial agents: back to the future? Can we live with only colistin, co-trimoxazole and fosfomycin?Clin Microbiol Infect20121811322168319
  • KaperJBNataroJPMobleyHLPathogenic Escherichia coliNat Rev Microbiol20042212314015040260
  • LivermoreDMHopeRBrickGLillieMReynoldsRNon-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001–2006J Antimicrob Chemother200862Suppl 2ii41ii5418819979
  • HöjgårdSAntibiotic resistance – why is the problem so difficult to solve?Infect Ecol Epidemiol2012218165
  • SoléMPitartCRocaIFirst description of an Escherichia coli strain producing NDM-1 carbapenemase in SpainAntimicrob Agents Chemother20115594402440421730115
  • NummilaKKilpeläinenIZähringerUVaaraMHelanderIMLipopolysaccharides of polymyxin B-resistant mutants of Escherichia coli are extensively substituted by 2-aminoethyl pyrophosphate and contain aminoarabinose in lipid AMol Microbiol19951622712787565089
  • SandersWSandersCCEnterobacter spp.: pathogens poised to flourish at the turn of the centuryClin Microbiol Rev19971022202419105752
  • MezzatestaMLGonaFStefaniSEnterobacter cloacae complex: clinical impact and emerging antibiotic resistanceFuture Microbiol20127788790222827309
  • KramerASchwebkeIKampfGHow long do nosocomial pathogens persist on inanimate surfaces? A systematic reviewBMC Infect Dis2006613016914034
  • VilaJMartíSSánchez-CéspedesJPorins, efflux pumps and multi-drug resistance in Acinetobacter baumanniiJ Antimicrob Chemother20075961210121517324960
  • Joly-GuillouMLClinical impact and pathogenicity of AcinetobacterClin Microbiol Infect2005111186887316216100
  • QueenanAMBushKCarbapenemases: the versatile β-lactamasesClin Microbiol Rev200720344045817630334
  • PoirelLNordmannPCarbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiologyClin Microbiol Infect200612982683616882287
  • PotronAPoirelLNordmannPEmerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiologyInt J Antimicrob Agents201545656858525857949
  • RuzinAKeeneyDBradfordPAAdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in Acinetobacter calcoaceticus–Acinetobacter baumannii complexJ Antimicrob Chemother20075951001100417363424
  • BonomoRASzaboDMechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosaClin Infect Dis200643Suppl 2S49S5616894515
  • AdamsMDNickelGCBajaksouzianSResistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component systemAntimicrob Agents Chemother20095393628363419528270
  • MoffattJHHarperMHarrisonPColistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide productionAntimicrob Agents Chemother201054124971497720855724
  • FothergillJLWinstanleyCJamesCENovel therapeutic strategies to counter Pseudomonas aeruginosa infectionsExpert Rev Anti Infect Ther201210221923522339195
  • AdairFWGefticSGGelzerJResistance of Pseudomonas to quaternary ammonium compounds. I. Growth in benzalkonium chloride solutionAppl Microbiol19691832993024984761
  • LivermoreDMWoodfordNThe β-lactamase threat in Enterobacteriaceae, Pseudomonas and AcinetobacterTrends Microbiol200614941342016876996
  • VahabogluHOztürkRAygünGWidespread detection of PER-1-type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter studyAntimicrob Agents Chemother19974110226522699333059
  • LaurettiLRiccioMLMazzariolACloning and characterization of blaVIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolateAntimicrob Agents Chemother19994371584159010390207
  • PoirelLMagalhaesMLopesMNordmannPMolecular analysis of metallo-β-lactamase gene bla(SPM-1)-surrounding sequences from disseminated Pseudomonas aeruginosa isolates in Recife, BrazilAntimicrob Agents Chemother20044841406140915047554
  • Rodríguez-MartínezJ-MPoirelLNordmannPExtended-spectrum cephalosporinases in Pseudomonas aeruginosaAntimicrob Agents Chemother20095351766177119258272
  • GirlichDNaasTNordmannPBiochemical characterization of the naturally occurring oxacillinase OXA-50 of Pseudomonas aeruginosaAntimicrob Agents Chemother20044862043204815155197
  • PoirelLNaasTNordmannPDiversity, epidemiology, and genetics of class D β-lactamasesAntimicrob Agents Chemother2010541243819721065
  • PhilipponLNNaasTBouthorsATBarakettVNordmannPOXA-18, a class D clavulanic acid-inhibited extended-spectrum β-lactamase from Pseudomonas aeruginosaAntimicrob Agents Chemother19974110218821959333046
  • SevillanoEGallegoLGarcía-LoboJFirst detection of the OXA-40 carbapenemase in P. aeruginosa isolates, located on a plasmid also found in A. baumanniiPathol Biol (Paris)200957649349518585868
  • El GarchFBogaertsPBebroneCGalleniMGlupczynskiYOXA-198, an acquired carbapenem-hydrolyzing class D β-lactamase from Pseudomonas aeruginosaAntimicrob Agents Chemother201155104828483321788473
  • HawkeyPFinchRTigecycline: in-vitro performance as a predictor of clinical efficacyClin Microbiol Infect200713435436217359318
  • SchwaberMJCarmeliYMortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysisJ Antimicrob Chemother200760591392017848376
  • NguyenMEschenauerGABryanMCarbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomesDiagn Microbiol Infect Dis201067218018420356699
  • QureshiZAPatersonDLPotoskiBATreatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimensAntimicrob Agents Chemother20125642108211322252816
  • DaikosGMarkogiannakisACarbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems?Clin Microbiol Infect20111781135114121635663